Anemia, a condition characterized by a decrease in the number of red blood cells (RBCs) or less than the normal quantity of hemoglobin in the blood, presents a diagnostic challenge to healthcare professionals due to its multifactorial etiology. This guide aims to provide a systematic approach to the diagnosis of anemia.
The initial evaluation of anemia should involve a thorough patient history, physical examination, and basic laboratory tests. The history should focus on potential causes such as nutritional deficiencies, chronic diseases, or blood loss. The physical examination can provide clues to the etiology, such as pallor, jaundice, or signs of underlying diseases. Basic laboratory tests include complete blood count (CBC) and reticulocyte count.
The CBC provides information about the RBC count, hemoglobin level, and hematocrit. The mean corpuscular volume (MCV) can categorize anemia into microcytic, normocytic, or macrocytic, guiding further diagnostic steps. The reticulocyte count indicates the bone marrow response to anemia. A high reticulocyte count suggests increased RBC destruction or loss, while a low count indicates decreased RBC production.
Depending on the initial findings, further diagnostic tests may include iron studies, vitamin B12 and folate levels, hemoglobin electrophoresis, bone marrow biopsy, or tests for hemolysis. It's crucial to tailor these investigations based on the patient's history, physical examination, and initial laboratory results.
Anemia is a complex disorder with a myriad of causes. A systematic approach to its diagnosis, starting from a thorough history and physical examination, followed by initial laboratory tests and further tailored investigations, is essential for healthcare professionals. Understanding the pathophysiological basis of anemia and the interpretation of laboratory tests is key to unraveling the complexity of this condition.
1.
Researchers use genomic technology to investigate aggressive skin cancer linked to burn scars
2.
The Growing Role of AI in Cancer Treatment
3.
Tafasitamab Regimen Improves PFS in Relapsed/Refractory Follicular Lymphoma
4.
Lower Prostate Cancer Mortality Linked to Unavailable Clinical Trials.
5.
Powerlifting through breast cancer: How a breast cancer survivor defied chemotherapy with strength training
1.
Drug Exposure in Tumor Microenvironments: Mechanisms, Clinical Implications, and Emerging Strategies
2.
Proteoform Networks in Blood Disorders: Mechanisms, Clinical Implications, and Emerging Therapeutic Strategies
3.
Antibody-Drug Conjugates and the Dawn of Targeted Cancer Therapy in 2025
4.
Revolutionizing Oncology Trials: Optimization, Matching, Diversity, and Decentralization
5.
Direct Oral Anticoagulants (DOACs) in Atrial Fibrillation: A Comprehensive Review
1.
International Conference on Innovations in Critical Care for Oncology and Cardiology
2.
International Conference on Oncology, Cardiology and Critical Care Policy
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
1.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion- Part II
2.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part IV
3.
Targeting Oncologic Drivers with Dacomitinib: A New Approach to Lung Cancer Treatment
4.
How Multidisciplinary Teams Support Modern Cancer Care
5.
Influence of CDK4/6 Inhibitors in Extending Progression-Free Survival (PFS) and Overall Survival in HR+/HER2- mBC Patients
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation